XOMA (XOMA)
(Delayed Data from NSDQ)
$25.28 USD
-1.42 (-5.32%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $25.56 +0.28 (1.11%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
XOMA Corporation [XOMA]
Reports for Purchase
Showing records 301 - 320 ( 330 total )
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Streamlining Initiatives Strengthen Focus On Core Assets And Makes Xoma An Attractive Acquisition Target In Our View. Reiterate OUTPERFORM.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The First of Three New Indications for Gevokizumab Is Acne. Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of December 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q3 Financials: Xoma Expands Gevokizumab Strategy To Include Larger Orphan Disease and New
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Anti-Botulism Program Progresses With New Federal Contract and Upcoming Data Presentations. Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
CEO Resigns But Clinical Programs Remain on Track
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Life Sciences MAC Best Ideas Conference - New York City - August 16 & 17, 2011 Day 2 - Key Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of August 7
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials Were Uneventful. We Project Cash Runway Through Mid-2012
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials Were Uneventful. We See Cash Runway Through Start of Phase 3 Behcet''s Uveitis Study by YE:11.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Phase 2b Results Put Diabetes Future in Question; However, Potential in Behcet''s Uveitis and Cardiovascular Diseases Reinforced.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
A FIVE STAR PATENTVEST IP GROWTH COMPANY - 2011 BEST AND BRIGHTEST PATENTVEST REPORTS
Provider: MDB CAPITAL GROUP LLC
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of March 6
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of January 16
Provider: WEDBUSH SECURITIES INC.
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
announced a regional partnership for XOMA-052 with Les Laboratoires Servier.
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: XOMA Corporation
Industry: Medical - Biomedical and Genetics
Recent Financing Extends Cash Runway Into Q3:11 and Through Major Clinical Value Drivers in Q1:11
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L